Neuren Pharmaceuticals (ASX:NEU) has announced the addition of SYNGAP1-related disorder to the development pipeline for its investigational therapy NNZ-2591, marking another step in the company’s strategy to target rare, genetically defined neurodevelopmental disorders. …
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5, Ep .24
July 17, 2026 - - Podcast -
Ex-Novartis leader joins the board of emerging nuclear medicine company
July 17, 2026 - - Latest News -
It doesn't always feel like it, but make no mistake, this is what winning looks like
July 17, 2026 - - Latest News -
Telix opens Australia's first integrated radiopharmaceutical facility in Melbourne
July 16, 2026 - - Latest News -
A single payer system in which the worst kind of inequity is the only one permitted
July 16, 2026 - - Latest News -
Organon and Samsung Bioepis expand partnership to broaden biosimilar access in Australia
July 16, 2026 - - Latest News -
Arthritis Australia unveils new grants and identity as research breakthroughs loom
July 16, 2026 - - Latest News